Cancer Care Moves Forward Amid COVID-19
Following the arrival of the coronavirus in the U.S., people with cancer and their doctors are adjusting to new ways of doing things while continuing to seek and provide cancer care.
Related Articles
Tunneling nanotubes and tumor microtubes—Emerging data on their roles in intercellular communication and pathophysiology: Summary of an International FASEB Catalyst Conference October 2023
The FASEB Journal publishes multidisciplinary basic and translational research covering biology and biomedical sciences at every level of organization.
The Promise of Liquid Biopsies | Cancer Today
Blood tests that detect traces of cancer cells and tumor DNA help find residual disease after treatment is completed.
Genetic Testing for Women With Breast Cancer | Cancer Today
A new guideline clarifies when women diagnosed with breast cancer should be offered genetic testing for inherited cancer risk.
National Doctors’ Day – AMA Alliance
National Doctors’ Day in the United States is a holiday which is celebrated on March 30th each year. It is a holiday that honors physicians…
What to Know About Rising Cancer Rates in Young Women
Kate Middleton’s diagnosis mirrors a worrying trend.
Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers
Lou and colleagues report a comprehensive analysis of 7,801 cases of colorectal cancer (CRC). They discovered significant differences in the tumor inflammatory microenvironment associated with…
Detailed Program | SRI 2024 Annual Meeting
President’s Distinguished Lecture I President’s New Investigator Plenary Supported by the Past Presidents’ Fund Moderators: Yoel Sadovsky, MD Kelle Moley, MD O-001: Maternal Extracellular Vesicle…
Tunneling nanotubes and tumor microtubes—Emerging data on their roles in intercellular communication and pathophysiology: Summary of an International FASEB Catalyst Conference October 2023
The FASEB Journal publishes multidisciplinary basic and translational research covering biology and biomedical sciences at every level of organization.
Tumor-Stroma Proportion Predicts Clinical Outcomes in Ovarian Cancer
A recent study found that tumor-stroma proportion was a reliable marker of chemoresistance, progression-free survival, and overall survival in high-grade serous ovarian cancer.
Progress in Rare Cancers | Cancer Today
With the rise of patient-driven registries, scientists are making advances in rare cancer research and treatment.
